Editas Medicine, Inc.

    Jurisdiction
    United States
    LEI
    5299000AON4Q9NT2JE42
    ISIN
    US28106W1036 (EDIT)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    InsiderPie Expert Score
    50 / 100
    Worse than peer group:
    56 / 100
    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    3 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    3 / 7

    Profile

    Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. Read full profile

    Fundamentals

    Net revenue
    €33.18M
    Gross margin
    92.3%
    EBIT
    -€204.68M
    EBIT margin
    -616.9%
    Net income
    -€202.03M
    Net margin
    -608.9%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €10.40M -68.7% -€91.05M -54.9%
    €5.28M -49.2% -€113.13M +24.2%
    €5.33M +1.0% -€128.22M +13.3%

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    No dividend payouts

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    Name Title Transaction Date Shares Price Value
    Burkly Linda EVP, CHIEF SCIENTIFIC OFFICER -710 $2.60 -$1.85K
    O'Neill Gilmore Neil CEO -5.6K $2.60 -$14.54K
    Parison Amy SVP, Chief Financial Officer -458 $2.60 -$1.19K
    Parison Amy SVP, Chief Financial Officer -679 $2.58 -$1.75K
    Burkly Linda EVP, CHIEF SCIENTIFIC OFFICER -5.1K $2.49 -$12.75K

    Earnings Calls

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 1M $1.20M -418K Sell

    Earnings Calls

    Latest earnings call: May 8, 2024 (Q1 2024)

    Add to watchlist

    Notifications